Radiopharmaceuticals Startup Secures $175M Funding
Aktis Oncology, a radiopharmaceuticals startup, raises $175M to advance targeted cancer treatments, focusing on specific tissues.
- Latest
- Trending
Aktis Oncology, a radiopharmaceuticals startup, raises $175M to advance targeted cancer treatments, focusing on specific tissues.
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Natera Inc. sees a 58% revenue surge in Q2 2024, driven by high test volumes and ASP growth, raising guidance ...
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
Explore promising biotech stocks like Vertex, Pfizer, and Merck, ready to innovate and grow in the evolving healthcare landscape.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.